Debra Resta
Impact in
- Hematology top 0.05%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Genetics top 0.05%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 19
- Chronic Myeloid Leukemia Treatments 13
- Hematopoietic Stem Cell Transplantation 6
- Genetics 9
- Chronic Lymphocytic Leukemia Research 8
- Co-authors
- Moshe Talpaz (9 shared papers)Brian Druker (8 shared papers)Renaud Capdeville (6 shared papers)Charles L. Sawyers (6 shared papers)Hagop M. Kantarjian (8 shared papers)J. Ford (5 shared papers)Bin Peng (2 shared papers)Elisabeth Buchdunger (2 shared papers)
- Journals
- Blood (5 papers)New England Journal of Medicine (3 papers)American Journal of Clinical Pathology (2 papers)Journal of Clinical Oncology (1 paper)Experimental Hematology (1 paper)
- Partner nations
- United StatesSwitzerlandGermany
In The Last Decade
Debra Resta
24 papers receiving 8.7k citations
Debra Resta's Hit Papers
Peers
Comparison fields: 5 of 115
- Hematology 5.9k
- Genetics 3.7k
- Rheumatology 2.5k
- Gastroenterology 379
- Oncology 1.6k
Countries citing papers authored by Debra Resta
This map shows the geographic impact of Debra Resta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debra Resta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debra Resta more than expected).
Fields of papers citing papers by Debra Resta
This network shows the impact of papers produced by Debra Resta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debra Resta. The network helps show where Debra Resta may publish in the future.
Co-authors
The 25 scholars most cited alongside Debra Resta, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia Hit paper breakdown → | 2001 | 3828 |
| 2 | Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome Hit paper breakdown → | 2001 | 2071 |
| 3 | Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia Hit paper breakdown → | 2002 | 1523 |
| 4 | Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Hit paper breakdown → | 2007 | 542 |
| 5 | 2004 | 374 | |
| 6 | 2002 | 227 | |
| 7 | 2003 | 95 | |
| 8 | Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. | 2002 | 85 |
| 9 | 2004 | 58 | |
| 10 | 1993 | 39 | |
| 11 | Recombinant human interleukin-3 (rhIL-3) enhances the mobilization of peripheral blood progenitor cells by recombinant human granulocyte colony-stimulating factor (rhG-CSF) in normal volunteers. | 1996 | 34 |
| 12 | 2003 | 29 | |
| 13 | Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF. | 1996 | 26 |
| 14 | 2003 | 15 | |
| 15 | 1994 | 14 | |
| 16 | 2006 | 14 | |
| 17 | Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lympoblastic leukemia with the philadelphia chromosome | 2001 | 9 |
| 18 | Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findings. | 1996 | 9 |
| 19 | 1995 | 8 | |
| 20 | 1995 | 7 |
About Debra Resta
Debra Resta is a scholar working on Hematology, Genetics, Immunology, Oncology and Rheumatology, having authored 24 papers that have together received 9.0k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (13 papers), Chronic Lymphocytic Leukemia Research (8 papers), Hematopoietic Stem Cell Transplantation (6 papers), Eosinophilic Disorders and Syndromes (4 papers), Neutropenia and Cancer Infections (4 papers), Hematological disorders and diagnostics (4 papers), Mast cells and histamine (2 papers) and Immune Cell Function and Interaction (2 papers). The work is most often cited by research in Hematology (5.9k citations), Genetics (3.7k citations), Rheumatology (2.5k citations), Gastroenterology (379 citations) and Oncology (1.6k citations). Debra Resta has collaborated with scholars based in United States, Switzerland and Germany. Frequent co-authors include Moshe Talpaz, Brian Druker, Renaud Capdeville, Charles L. Sawyers, Hagop M. Kantarjian, J. Ford, Bin Peng, Elisabeth Buchdunger, Sayuri Ohno-Jones and Nicholas Lydon. Their work appears in journals such as Blood, New England Journal of Medicine, American Journal of Clinical Pathology, Journal of Clinical Oncology and Experimental Hematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.